We identified quantitative trait loci (QTL) that determined the genetic variance in serum IGF-I through genome-wide scanning of mice derived from C57BL/6J(B6) ؋ C3H/HeJ(C3H) intercrosses. One QTL (Igf1s2), on mouse chromosome 10 (Chr10), produces a 15% increase in serum IGF-I in B6C3 F2 mice carrying c3 alleles at that position. We constructed a congenic mouse, B6.C3H-10 (10T), by backcrossing c3 alleles from this 57-Mb region into B6 for 10 generations. 10T mice have higher serum and skeletal IGF-I, greater trabecular bone volume fraction, more trabeculae, and a higher number of osteoclasts at 16 wk, compared with B6 (P < 0.05). Nested congenic sublines generated from further backcrossing of 10T allowed for recombination and produced four smaller sublines with significantly increased serum IGF-I at 16 wk (i.e. 10-4, 10-7, 10-10, and 10-13), compared with B6 (P < 0.0003), and three smaller sublines that showed no differences in IGF-I vs. age-and gender-matched B6 mice. Like 10T, the 10-4 nested sublines at 16 wk had higher femoral mineral (P < 0.0001) and greater trabecular connectivity density with significantly more trabeculae than B6 (P < 0.01). Thus, by comprehensive phenotyping, we were able to narrow the QTL to an 18.3-Mb region containing approximately 148 genes, including Igf1 and Elk-3(ETS domain protein). Allelic differences in the Igf1s2 QTL produce a phenotype characterized by increased serum IGF-I and greater peak bone density. Congenic mice establish proof of concept of shared genetic determinants for both circulating IGF-I and bone acquisition. (Endocrinology 147: 3915-3923, 2006)
C IRCULATING IGF-I IS A COMPLEX trait with multiple
genetic and environmental determinants (1) . Studies in mice, baboons, rats, and humans have also demonstrated strong heritability for bone mineral density (BMD) and peak skeletal acquisition, although identifying those genes has not been straightforward (2) (3) (4) . Igf1 is an attractive candidate gene for bone acquisition because it is a circulating and skeletal mediator of GH action (5) . Targeted genomic studies have confirmed the importance of skeletal IGF-I for the osteoblast differentiation program and osteoclastogenesis (6 -8) . Similarly, circulating IGF-I affects bone modeling and appears to cosegregate with BMD in several mouse models (1, 5, 9 -11) . Support for the premise that genetic regulation of circulating IGF-I may play an important role in peak bone acquisition comes from both human and mouse studies. In the former, several polymorphisms in the P1 promoter and the 3Ј-untranslated region of the Igf1 gene have been associated with BMD, skeletal geometry, and serum IGF-I (9, 10) . In respect to the latter, studies with inbred strains of mice have demonstrated strong heritability for the serum IGF-I phenotype and a close correlation with volumetric femoral BMD (vBMD) (11, 12) . Recently we reported that differences in serum IGF-I between two inbred strains of mice were due to increased P2 promoter activity of the Igf1 gene, thereby suggesting that heritability of this phenotype was related to one or more genetic determinants functioning either as cis or trans acting factors to regulate gene transcription (13, 14) .
To overcome the difficulty in finding genes that influence IGF-I, we turned to a quantitative trait locus (QTL) approach using two inbred strains of mice. As reported previously, C3H/HeJ (C3H) female mice have greater serum IGF-I concentrations as well as higher vBMD than C57BL/6J (B6) during and after development (2, 11, 12, 15) . By crossing C3H and B6 and then intercrossing B6C3F1 mice, we identified several QTL in the female F2 progeny that independently segregated for serum IGF-I and femoral BMD (2, 12) . Three QTL for IGF-I were found to contribute about 50% of the variance across the two strains and two of these (i.e. Igf1s1, Igf1s2) could be superimposed on femoral BMD QTL (2, 12) . Previously we reported genomic and functional studies for one congenic strain, B6.C3H-6T (i.e. 6T, which carries the Igf1s1 QTL) (16 -19) . In this study, we examined the IGF-I and skeletal phenotypes of a second congenic mouse strain, B6.C3H-10 (i.e.10T). This strain carries the Igf1s2 QTL on a B6 background with C3H alleles from the midportion of chromosome (Chr) 10 . Based on previous F2 data for both the serum IGF-I phenotype and vertebral trabecular bone volume fraction (BV/TV), we predicted, a priori, that a congenic strain with this 30-cM region of the Chr 10 genome from C3H would show increased serum IGF-I and greater bone mass (12, 15) . Findings from several nested congenic sublines indicated that allelic differences in this QTL profoundly affect both circulating IGF-I and skeletal remodeling.
Materials and Methods Mice
The progenitor inbred strains, C3H/HeJ(C3H) and C57BL/6J(B6), are available from The Jackson Laboratory (Bar Harbor, ME; C3H (Jax Research no. 000659) and B6 (Jax Research no. 000664). BMD and IGF-I data on these two strains have been published previously (2, 11, 15) . The congenic strain, B6.C3H-10T (10T), was generated by introgressing a region of Chr 10 from C3H into a B6 background for 10 generations. This region contains Igfsl2, a QTL affecting serum IGF-I (12). Recombination of 10T mice through intercrossing brother-sister pairs led to the generation of 10T sublines, numbered by their production. Currently there are eight sublines (10-1, 10-2, 10-3, 10-4, 10-5, 10-7, 10-10, 10-13) that have been fully genotyped and phenotyped for serum IGF-I at 8 and 16 wk of age. There are two congenic sublines with complete skeletal phenotyping: 10T and 10-4. Bone parameters in the sublines reported in this study, i.e. 10T and 10-4, are always compared with age-and gendermatched B6 progenitors. The animal protocol was approved by Institutional Animal Care and Use Committee at The Jackson Laboratory.
Phenotyping
Dual-energy x-ray absorptiometry (DXA) scanning by PIXImus. We used PIXImus (GE-Lunar, Madison, WI) to assess areal whole-body BMD and body composition in 10T congenic and B6 control mice at 8 and 16 wk of age. This methodology has been validated in small animals. PIXImus scanning in mice for bone mineral content (BMC) and percent fat is both accurate and precise, although size must be considered when comparing strains. BMC by PIXImus is highly correlated with mineral content of hydroxyapatite standard of known density (r 2 ϭ 0.997).
Peripheral quantitative computed tomography (pQCT) for volumetric femoral BMD. vBMD was measured on the entire left femur from groups of female and male B6 and congenic mice. Isolated femur length was measured with digital calipers (Stoelting, Wood Dale, IL), and then femurs were measured for density using the SA Plus densitometer (Orthometrics; Stratec SA Plus Research Unit, White Plains, NY). Calibration of the SA Plus instrument was done with hydroxyapatite standards of known density (50 -1000 mg/mm 3 ) with cylindrical diameters 2.4 mm and length 24 mm. Assessment of defined thickness aluminum foils indicated accurate measurement of the 0.25-mm-thick foil, whereas a 0.02-mm-thick foil could not be measured. The bone scans were analyzed with two different sets of thresholds to separate bone from soft tissue. Outer high density thresholds of 710 and 570 mg/cm 3 were used to determine cortical bone areas and surfaces. This threshold was selected to yield area values consistent with histomorphometrically derived values. To determine mineral content, a second analysis was carried out with threshold settings of 220 and 400 mg/cm 3 . These lower thresholds were selected so that mineral from most partial voxels (0.07 mm) would be included in the analysis. Density values were calculated from the summed areas and associated mineral contents. Precision of the SA Plus for repeated measurement of a single femur was found to be 1.2%. Isolated femurs were scanned at seven locations at 2-mm intervals, beginning 0.8 mm from the distal ends of the epiphyseal condyles. Due to variation in femur lengths, the femoral head and necks could not be scanned at the same location for each bone and thus was not included in final data. Total vBMD values were calculated by dividing the total mineral content by the total bone volume (bone ϩ marrow) and expressed as milligrams per cubic millimeter. Periosteal perimeters and cortical thickness data were obtained at the midshaft scan.
MicroCT (micro-computed tomography) 40 femoral cross-sectional geometry and trabecular morphology. Femurs from age-, genotype-, and gendermatched mice were scanned using a microCT40 microcomputed tomographic instrument (CT40, Scanco Medical AG, Bassersdorf, Switzerland) to evaluate cross-sectional geometry at the femoral midshaft and trabecular bone volume fraction and microarchitecture in the secondary spongiosa of the distal femur (15) . The femurs were scanned at low resolution, energy level of 55 KeV, and intensity of 145 A. Eighteen slices were measured at the midpoint of each femur, with an isotropic pixel size of 12 m and slice thickness of 12 m, and used to compute the average total cross-sectional area (square millimeters), bone area (square millimeters), marrow area (square millimeters), and cortical thickness (micrometers). Images of the distal femur were acquired at the same parameters as the femoral midshaft. BV/TV and microarchitecture were evaluated in the secondary spongiosa, starting at approximately 0.6 mm proximal to the growth plate and extending proximally 1.5 mm.
IGF-I measurements
Serum IGF-I was measured by a RIA (ALPCO, Windham, NH) (16) . IGF binding proteins (IGFBPs) were first separated from the IGF-I by an acid dissociation step. This was followed by the addition of a neutralization buffer containing excess recombinant human IGF-II, allowing the IGF-II to bind to the IGFBPs before immunoassay with a human anti-IGF-I polyclonal antibody. The sensitivity of the assay is 0.01 ng/ml IGF-I; the interassay coefficient of variation based on normal standards and pooled serum of C3H and B6 is approximately 6%. There is no cross-reactivity with IGF-II. Standards were included in each assay as well as normal pools from both progenitors. Because of the large numbers of samples run for IGF-I, all values were adjusted to the standard B6 mouse pools using a correction factor to account for interassay variation. In addition to serum measurements, IGF-I in conditioned media was measured using the same assay; the results were then corrected for milligrams of protein in the conditioned medium (i.e. nanograms per milligram of protein).
Quantitative PCR
Samples of liver and bone tissue from 8-wk 10T and B6 controls male mice were extracted for RNA as previously described (17) . Briefly, total RNA was isolated from liver and bone using the Total RNA isolation system (Promega, Madison, WI) as per the manufacturer's instructions. RNA was DNAase treated and subsequently purified further using RNA Easy spin columns (QIAGEN, Valencia, CA). RNA quality and quantity were assessed using an Agilent bioanalyzer (Caliper Technologies Corp., Hopkinton, MA). Five hundred nanograms of RNA was converted to cDNA in a reverse transcription reaction, using Superscript II (no. 18064-014; Invitrogen, Carlsbad, CA) and random hexamers as primers as per the manufacturer's direction. The cDNA was then diluted 1:5 with water. For each PCR, 1 l of diluted cDNA was added to 5 l of 2 ϫ iTaq SYBR Green Supermix with ROX (catalog no. 170-8851; Bio-Rad Laboratories, Hercules, CA) and 100 nm of each forward and reverse primer in a total reaction volume of 10 l. Cycling conditions were 2 min hold at 50 C; 3 min hold at 95 C; 40 cycles of 95 C, 15 sec; 60 C, 1 min; and all reactions were run on the ABI 7900HT sequence detection system (Applied Biosystems, Warrington UK). Each of the 48 sets of genespecific primers was analyzed by real-time PCR to assess transcript levels, with each primer pair run once per biological replicate. Four biological replicates were run per strain. Differential expression was assessed using a global pattern recognition algorithm (GPR) as previously described (20) . In short, the global pattern recognition algorithm assesses each gene as a potential normalizer for all other genes on the run. It then calculates a score based on the fraction of normalizers against which a given gene was found to be significantly different. Fold change is then calculated as previously described (20, 21) . In this manner the statistical significance of an observed expression level difference is assessed before fold change is calculated. With numerous normalizers used per examined gene, biases based on any one normalizer are eliminated.
IGF-I RNase protection assay
A 386-bp DNA fragment consisting of the 3Ј end of intron 1, the entire 72 bp of exon 2, the contiguous 241 bp containing exon 3, and the 5Ј end of exon 4 was obtained from a mouse IGF-I clone and was subcloned into pGEM 2 (13) . The plasmid was linearized with EcoR1, and T7 RNA polymerase was used to synthesize a 32 P-labled antisense RNA using ␣-32 P-UTP (DuPont NEN Life Science Products, Boston, MA) and re-agents from Ambion, Inc. (Austin, TX). The probe was hybridized with equivalent amounts of total RNA. Hybridization, subsequent RNase digestion of unhybridized RNA and collection, and electrophoresis of protected probe fragments were carried out as described by Adamo et al. (13) . Hybridization of the probe to IGF-I mRNAs yields a protected band of 241 nt, reflecting exon 1 transcripts, and a series of bands ranging from approximately 290 to approximately 310 bp, reflecting IGF-I mRNAs initiated from the clusters of exon 2 start sites. RNase protection assays (RPA) for mouse actin used a construct, also supplied by Ambion.
Histomorphometry
Femurs were dissected free of tissue and fixed in 4% paraformaldehyde at the time the animals were killed. The undecalcified femurs were then dehydrated in increasing concentrations of ethanol, cleared in xylene, and embedded in methyl methacrylate. Five-micrometer-thick longitudinal serial sections were cut on a Reichert-Jung Polycut S microtome (Reichert-Jung, Heidelberg, Germany). Sections were taken from the middle of the femur, in which a central vein is located. Some sections were stained with modified Masson trichrome stain for static measurements (22) . Histomorphometric measurements were made in a blinded, nonbiased manner using the OsteoMeasure computerized image analysis system (OsteoMetrics, Inc., Atlanta, GA) interfaced with an Optiphot Nikon microscope (Nikon Inc., Melville, NY) at a magnification of ϫ20. The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (23) . All measurements were confined to the secondary spongiosa and restricted to an area between 400 and 2000 m distal to the growth plate-metaphyseal junction of the distal femur. Cortical measurements were made 4000 m distal to the same growth plate.
Adult bone marrow stromal cell cultures for IGF-I
Bone marrow was removed from 10T and B6 8-wk-male mice and immediately plated in dishes. Adherent cells were removed after 2 d, and these cells were plated in six-well dish plates and cultured for 7 d in DMEM and 10% fetal calf serum with medium change at d 3. After 7 d, medium was replaced with ␣MEM, glycerophosphate, and phosphoascorbate. After 24 h, the conditioned medium is removed and assayed for both IGF-I and protein content.
Statistics
Data are expressed as mean Ϯ sem in tables and figures. Statistical evaluation was performed using the JMP (SAS, Cary, NC) ANOVA software program for ANOVA and for linear model regression analyses. The pQCT data were adjusted for effects of body weight and femur length, whereas the DXA (PIXImus) data were adjusted for effects of body weight. Differences between adjusted least squares means for B6 and each congenic subline were tested by Student's t test, with significance declared when P Ͻ 0.05 was observed. Differences between 8 and 16 wk in serum IGF-I for B6 and the congenic sublines were also tested by ANOVA.
Results

10T congenic mice: circulating, skeletal, and hepatic expression of IGF-I
Congenic 10T mice (N10F2) were generated by introgressing the locus on Chr 10 (i.e. Igf1s2) into a B6 background for 10 generations; details of this technique have previously been reported by our group and others (15) . Congenic 10T mice have a background that is 99.6% B6 but carry C3H (c3) alleles at one locus (i.e. midregion of Chr 10); they do not differ from B6 with respect to birth weight, reproductive capacity, or food consumption. At 8 wk, there was a trend for male 10T mice to have slightly but not significantly greater levels of IGF-I than B6 (P ϭ 0.20); female 10Ts at 8 wk did not differ from B6 (P ϭ 0.90). But at 16 weeks, we noted higher serum IGF-I concentrations in both male and female 10T mice, compared with age-matched B6 (n ϭ 15 mice per genotype per gender; male 10T: 280 Ϯ 8 vs. B6: 233 Ϯ 7 ng/ml; P ϭ 0.0002; female 10T: 287 Ϯ 10 vs. B6: 265 Ϯ 7 ng/ml P ϭ 0.09). At 20 wk of age, 10T mice of both genders (n ϭ 15 per gender) showed significant differences from B6: male 10T: 330 Ϯ 5.9 vs. B6: 304 Ϯ 5.6 ng/ml; P ϭ 0.002; female 10T: 341 Ϯ 8.8 vs. B6: 317 Ϯ 6.9 ng/ml, P ϭ 0.03. Despite these IGF-I strain differences, no consistent changes in circulating IGFBPs for 10T, compared with B6, were noted at 16 wk as measured by Western ligand blot (data not shown).
The differences in serum IGF-I were mirrored by expression changes in the liver as determined by RPAs. Eight-week 10T male mice (n ϭ 6 per strain) showed significantly increased exon 2 transcripts of the Igf1 gene, compared with B6 (n ϭ 4) (P Ͻ 0.05) (Fig. 1) , a pattern identical with what has been reported for progenitor C3H hepatic transcripts of Igf1 (13) . RT-PCR of 8-wk male liver from 10T and B6 confirmed a 1.8 Ϯ 0.6-fold greater expression of Igf1 mRNA in 10T vs. B6 (P Ͻ 0.05). Similarly, in three determinations of 8-wk whole femorae (i.e. cortical and trabecular bone plus marrow contents), skeletal Igf1 mRNA by RT-PCR was 1.33 Ϯ 0.08-fold greater in 10T than B6 (P Ͻ 0.05). Expression differences in IGF-I in whole bone were also reflected by strain differences in secreted IGF-I from conditioned media of adult bone marrow stromal cells (i.e. 10T IGF-I secreted: 579 Ϯ 41 ng/mg protein vs. B6 IGF-I secreted: 350 Ϯ 20 ng/mg protein, P Ͻ 0.01). Finally, two important skeletal factors also showed differential strain expression by quantitative PCR of long bones. In 10T mice, Runx2, a bone-specific transcription factor necessary for osteoblast differentiation, exhibited 1.63-fold greater mRNA expression relative to B6 (P Ͻ 0.05), whereas message for IGFBP-5, an IGFBP regulated by IGF-I, was 2.12-fold higher in 10T than B6 femorae (P Ͻ 0.05). Thus, serum IGF-I as well as hepatic and skeletal expression of IGF-I was greater in 10T than B6, a pattern also seen in C3H mice (13) . Moreover, these strain differences were reflected in secreted IGF-I from adult marrow cells and the expression in bone of two downstream targets of IGF-1 activity, IGFBP-5 and Runx2.
Body composition and skeletal phenotyping of 10T
To determine how allelic changes in circulating and skeletal IGF-I affected body composition, we performed DXA scans by PIXImus in 16-wk 10T and B6 male and female mice. Female 10T mice had modestly higher lean body mass (P Ͻ 0.08 vs. B6) and slightly greater percent BMC, compared with B6, even though total body weight did not differ (Table 1) . Volumetric BMD of the total femur and midshaft was measured by pQCT. 10T females had nearly identical femoral size as B6 females, with slightly but not significantly greater cortical thickness; there were no differences in cortical bone density or periosteal circumference between strains. Male 10Ts were not different from male B6 for any cortical parameter (data not shown).
When distal femoral BV/TV was measured by microCT, the strain differences between 10T and B6 were gender dependent. Female 10T had significantly higher trabecular BV/TV and trabecular number at 16 wk, compared with B6 (P Ͻ 0.01; see Table 2 ). For male 10T mice, BV/TV was slightly but not significantly higher vs. B6, but like female 10T, trabecular number was markedly increased (P Ͻ 0.005) and there was a trend toward lower structure model index (SMI) ( Table 2) . We next performed dynamic bone histomorphometry from the distal femur of 16-wk congenic and B6 males and females (n ϭ 11/strain). Once again, we found that female 10T mice had higher distal femoral BV/TV than B6 (P Ͻ 0.05). Also, the number of osteoclasts per bone perimeter and per bone surface was markedly increased in 10T females, compared with B6 females (P Ͻ 0.01). On the other hand, for males, there were strain differences, compared with B6, that paralleled female 10T changes, but these were not statistically significant (see Table 3 ).
Generation of nested congenic sublines for mapping and phenotyping
Because the Igf1s2 QTL mapped by F2 analysis spanned more than 57 Mb of the C3H genome and was carried in the 10T strain, we estimated that more than 500 genes could be contributing to the phenotypic differences between 10T and B6. Hence, to narrow the genomic region and reduce the number of potential candidate genes, we generated nested sublines by backcrossing 10T to B6 and then fixing the recombinants (Fig. 2) . We chose to study female nested congenics for two reasons: 1) we mapped the Igf1s2 QTL in females only (12); and 2) differences in trabecular bone mass by microCT and histomorphometry were greatest in females. Fixed nested congenics as determined by comprehensive genotyping in the Chr 10 locus (see Fig. 2 ), were then tested for serum IGF-I at both 8 and 16 wk using a minimum of 10 mice per subline per age. We found that serum IGF-I at 8 wk was significantly greater in female 10-4, 10-7, 10-10, and 10-13 than B6 (P Ͻ 0.05 by ANOVA), and at 16 wk, sublines 10-4, 10-7, 10-10, and 10-13 were markedly greater than B6 (i.e. Ͼ 20% higher; P Ͻ 0.0003 by ANOVA; Fig. 3 ).
In the 10-4, 10-7, 10-10, and 10-13 nested sublines, serum IGF-I either increased or stayed the same between 8 and 16 wk of age, a finding similar to C3H progenitors measured during that same growth period (11) . On the other hand, serum IGF-I in the B6 females consistently declined by at least 10% between 8 and 16 wk (P ϭ 0.03 for serum IGF-I in B6 between 8 and 16 wk). Thus, the nested congenic sublines provided further proof of a small locus in the midregion of Chr 10 containing one or more genes that affected circulating IGF-I and was temporally regulated.
Skeletal phenotyping of the 10-4 subline
To determine whether the skeletal phenotype was carried in the first set of nested sublines with the highest IGF-I levels, we measured femoral vBMD and BV/TV at 16 wk in sublines with a minimum of 10 mice/strain; i.e.:10-1, 10-2, 10-3, 10-4, and B6 controls. Only subline 10-4 showed statistically significant differences in measurements of trabecular bone by microCT and cortical bone by pQCT from B6. Distal femoral bone volume, total femoral mineral, midcortical density, trabecular number, connectivity density, and SMI were all significantly different in 10-4, compared with B6 (P Ͻ 0.02 vs. B6 for all parameters, see Table 4 ). Other nested sublines showed no differences in trabecular or cortical parameters when compared with B6 (data not shown). Hence, greater circulating IGF-I in at least one nested subline was associated with enhanced bone mineral and mass.
Candidate genes in the Chr 10 QTL
The Chr 10 QTL is approximately 57 Mb in size, whereas the 10-4 region is less than 33 Mb. The latter region contains approximately 300 known genes and expressed sequence tags. However, with subline phenotyping for serum IGF-I, we were able to narrow the region to approximately 18.3 Mb and 148 genes (see Supplemental Fig. 1 , published on The Endocrine Society's Journals Online web site at http:// endo.endojournals.org). As shown in Fig. 2, 10-7 , 10-10, and 10-13 have higher serum IGF-I than B6 at both 8 and 16 wk, whereas 10-1, 10-2, and 10-5 do not. The most obvious candidate gene carried within the sublines that show higher serum IGF-I is Igf1 itself (Fig. 4) . However, three other genes are of interest: Socs2, which is an inhibitor of growth hormone signaling; Elk-3 (Ets domain protein), which is an activator of transcription in the IGF-I signaling pathway; and Kitl (Kit ligand), which can stimulate osteoclastogenesis. Finally, it is worth noting that QTL for two other phenotypes that may be regulated by IGF-I, vertebral BV/TV and whole-body growth, have also been mapped to this region (15, 24; and http://www.informatics.jax.org) (see Fig. 4 ). Thus, using sublines as mapping tools, we can narrow the list of candidate genes and subsequently determine by differential expression and sequence analysis the genetic determinants of IGF-I within this locus.
Discussion
In this study, using the congenic 10T strain and its nested sublines as models, we demonstrated that allelic determinants in a gene or genes from the mid region of Chr 10 profoundly affect serum IGF-I and bone acquisition. We built the 10T congenic by introgressing about 57 Mb of the C3H genome on Chr 10 onto a B6 background. Two major phenotypes were considered a priori, IGF-I and BV/TV; these predictions were based on our previous F2 analysis of nearly 1000 female mice (12, 15) . In fact, we found increased circulating IGF-I concentrations in the congenic 10T as well as parallel changes in hepatic and skeletal IGF-I mRNA expression across several ages. With respect to the skeletal phenotypes of the congenics, 10T female mice at 16 wk had significantly greater BV/TV and trabecular number, compared with B6. This was accompanied by histomorphometric evi- dence of greater numbers of osteoclasts but not osteoblasts. Taken together, these lines of evidence suggested that 10T mice had a high turnover skeletal phenotype, accompanied by increased serum and skeletal IGF-I. This conclusion is supported by generation of at least one nested congenic subline, 10-4, that recapitulated virtually all of the skeletal phenotypes found in the 10T congenic as well as the increase in serum IGF-I. Moreover, sublines carrying even smaller regions of C3H on a B6 background from recombination within the QTL (10-7, 10-10, 10-13) exhibited even higher serum IGF-I at 16 wk of age than age-and gender-matched B6 controls (i.e. a Ͼ 20% increase over B6 controls). Our data provide the first in vivo evidence of a functional relationship between allelic differences in IGF-I and bone acquisition. Unlike knockout or transgenic models, congenic mice exhibit only modest differences in circulating and skeletal IGF-I expression. Yet in many ways, the phenotypic feature of these mice parallel changes seen with targeted genomic strategies. For example, we recently showed that targeted overexpression of Igf1 to bone using a Col1A1 promoter led to greater bone remodeling and increased osteoclastogenesis in adult mice, a finding remarkably similar to the 10T and 10-4 sublines (6). Thus, congenics provide proof of concept that a QTL in the midregion of mouse Chr 10 has a significant effect on both IGF-I expression and bone acquisition.
Because congenics carry allelic differences in a single locus, these mice also reflect the genetic heterogeneity inherent in the human population, thus providing a platform for understanding how heritable differences in IGF-I impact the skeleton (26) . For example, the syntenic chromosomal region for mouse Chr 10 in humans is Chr12 q 21-24, which has been reported to have a major femoral BMD QTL in at least three human cohorts (1, 3, 4, 27) . And single-nucleotide polymorphisms in the Igf1 gene have recently been associated with both femoral BMD and circulating IGF-I in a large Chinese sibling cohort (28) . Moreover, data from the current study are consistent with recent work identifying a QTL for BV/TV in B6C3F2 progeny in the same region as the Igf1s2 QTL (15) . Two other groups have found BMD QTL in the midregion of Chr 10 in different inbred strain crosses, and Klein et al. identified a femoral moment of inertia QTL between B6 and DBA/2 in the same region (29, 30, 31) . Hence, there appears to be a conserved locus on mouse Chr 10 in mice and humans that affects both IGF-I and skeletal acquisition.
The phenotypic features of our congenics raise several important and provocative questions. First, there was some degree of gender specificity for the skeletal phenotypes of the   FIG. 2 . Nested congenic sublines generated from the 10T congenic. Genetic markers (Mit markers and single-nucleotide polymorphisms) are represented on the y-axis, and on the x-axis, the sublines that were generated to date, and their position on Chr 10 adjacent to their identification. The four major candidate genes are noted in bold. Igf1 is located at 88.7 Mb on this map. Nested sublines 10-15, 10-6, and 10-12 have recently been generated and are being phenotyped.
sublines. For example, serum IGF-I was increased in both males and female 10T, but differences in BV/TV and osteoclast number, compared with B6, were more pronounced in 10T females than 10T males. A similar pattern was noted in the nested congenic subline 10-4, i.e. females exhibited marked increases in trabecular number and connectivity density with increased serum IGF-I, compared with B6, whereas male 10-4 mice showed slightly greater trabecular bone mass but significantly increased serum IGF-I in relation to B6.
Gender specificity for skeletal phenotypes has been described previously (24) . Both Klein et al. and our group (17, 31) have reported gender differences for peak bone mass and serum IGF-I among congenic strains. The mechanisms surrounding this feature of QTL analysis are not clear yet are probably more frequent than reported. It should be noted that we mapped QTL for BMD and IGF-I in the original B6C3F2 progeny by phenotyping female mice only (12) . Hence, we do not know whether male F2 mice would have a QTL for serum IGF-I and BMD in the same mid region of Chr 10. But QTL studies in progress, particularly in lit/lit mice on a C3H and B6 background, may help define gender specificity and its relationship to the GH/IGF-I axis (32) .
We still to need clarify the relationship between genes controlling circulating IGF-I and those influencing bone acquisition. The Chr 10 QTL region represents approximately 57 Mb of genomic DNA with hundreds of genes that could influence both IGF-I and bone mass. Conversely, the QTL may possess two sets of genes for these phenotypes: one that regulates IGF-I expression and one that independently contributes to bone acquisition. Only through extensive skeletal phenotyping of the congenic sublines (e.g. 10-7 or 10-10), which carry a much narrower genomic region than 10-4, will we be able to determine how many genes may be present in this region and which ones regulate circulating and/or skeletal IGF regulatory pathways. Those studies are currently ongoing.
Another surprising finding was the developmental differences in serum IGF-I in the nested congenic sublines, compared with B6 progenitors. Several years ago we noted that in B6 females, between 8 and 16 wk, there was a modest but statistically significant decline in circulating IGF-I, not seen in female C3H mice (11) . As we developed congenic sublines including 10T, we noted that differences in serum IGF-I in these strains were considerably greater at 16 than 8 wk of age, compared with age-matched B6 controls (i.e. Ͼ 20%). This was due to a decline in serum IGF-I for B6 during the late phases of pubertal growth, whereas serum IGF-I in the sublines either did not change or increased. Similarly, the bone phenotype in the congenics was much more pronounced at 16 vs. 8 wk of age. These developmental differences resemble changes in female C3H mice during this period and strongly suggest that the genomic region of interest in mouse Chr 10 is temporally regulated. Whether this is due to enhanced growth hormone sensitivity, changes in sex steroids, or other factors remains to be determined.
With respect to identifying where the alleles are positioned that result in the IGF-I and skeletal phenotypes of the congenics, there are several plausible candidate genes. The 10T, 10-4, 10-7, 10-10, and 10-13 congenic mice all carry Igf1 alleles from C3H, making it conceivable that a cis-acting polymorphism within that gene, or an enhancer adjacent to the Igf1 gene, could affect transcriptional activity. We previously found a polymorphic sequence in the P1 promoter B6 in the Igf1 gene that differed between C3H and that may be re- (35) . However, several lines of evidence suggest that Socs-2 is not a candidate gene. First, before narrowing the sublines, we measured hepatic Socs-2 expression by RPA in 10T and found slightly higher levels in 10T vs. B6 (Adamo, M. L., personal communication). This would not be consistent with either the skeletal or IGF-I phenotype of 10T or 10-4. Second, the 10-7 subline does not carry the Socs-2 gene yet has higher serum IGF-I than B6. Thus, we suspect Socs-2 is not the gene driving the skeletal or IGF-I phenotypes in the 10 sublines. But the proximity of this gene to Igf1 demonstrates how structural aspects of the mammalian genome align nicely with functional components.
We can eliminate another candidate, Kitl, a protein that can stimulate osteoclast recruitment because it is outside the locus identified from our new sublines (see Fig. 2 ). On the other hand, Elk-3, a transcription factor, is located closer to the Igf1 gene and currently cannot be excluded. There is one report (36) of a targeted mutation in Elk-3 that is associated with early lethality due to vascular defects and chylothorax. Although this gene is an unlikely candidate, it is conceivable that the Igf1s2 QTL could carry a gene such as Elk-3, which targets expression of early genes in development, and thereby affects peak bone mass by up-regulating IGF-I transcription (36) . Indeed, our group recently reported a strong QTL for areal BMD in the same region on Chr 10(i.e. ϳ60 cM) in F2 female mice from a B6 ϫ 129 cross (29) . This would imply conservation across inbred strains of a gene or genes that affect peak bone acquisition.
Finally, with respect to the skeletal phenotype, several lines of evidence suggest there may be increased osteoclastic activity in the 10T and 10-4 congenic female mice. We found that 16-wk 10T females had higher BV/TV than B6; this was associated with greater numbers of osteoclasts and more trabeculae. The 10-4 subline also had more trabeculae, greater bone volume, lower SMI, and increased trabecular connectivity, compared with B6. These findings would be consistent with a high bone turnover state, particularly by 16 wk of age, a time when there are major differences in circulating IGF-I, compared with the progenitors. Whether these findings are related to increased skeletal IGF-I expression in all the major sublines is not clear yet. Nevertheless, IGF-I can stimulate bone remodeling and particularly bone resorption when administered exogenously to mice and rats or when overexpressed in bone (37) . The mechanism for IGF-I induction of osteoclastogenesis is not well delineated, but IGF-I can stimulate receptor activator of nuclear factor-B ligand expression in ST-2 cells (25) . Further studies will more clearly define the skeletal phenotype in the nested congenic sublines and the role of IGF-I in bone remodeling. In summary, we generated nested congenic mice that have increased circulating IGF-I and a pronounced skeletal phenotype. These sublines are important model systems not only for dissecting the relationship between allelic differences in local/systemic IGF-I and bone acquisition but also for identifying heritable determinants of IGF-I expression. 
